Subtype
Glioma
CI-CAN-00000935Explore in graph →
Non-malignant787 active trials5 approved drugs147 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000935Explore in graph →
Clinical trials
2,804 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00290771 | Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM) | terminated | Phase 2 | 231 | NovartisINDUSTRY | 1 | May 16, 2011 | clinicaltrials |
| NCT01181193 | Vitamin D for Treatment of Glioblastoma Multiforme | unknown | Phase 1 / Phase 2 | 20 | Soroka University Medical CenterOTHER | 1 | Mar 29, 2011 | clinicaltrials |
| NCT00635557 |
| Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme |
| unknown |
| Phase 1 / Phase 2 |
| 30 |
| Myrexis Inc.INDUSTRY |
| 1 |
| Mar 25, 2011 |
| clinicaltrials |
| NCT01308632 | Metronomic Temozolamide in Patients With Recurrent Glioblastoma | unknown | Phase 2 / Phase 3 | 30 | Grupo Español de Investigación en NeurooncologíaOTHER | 0 | Mar 4, 2011 | clinicaltrials |
| NCT00520936 | A Study of Pemetrexed in Children With Recurrent Cancer | completed | Phase 2 | 72 | Eli Lilly and CompanyINDUSTRY | 1 | Feb 25, 2011 | clinicaltrials |
| NCT00238797 | A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme | completed | Phase 2 | 36 | AstraZenecaINDUSTRY | 1 | Jan 21, 2011 | clinicaltrials |
| NCT01252459 | Amino-acid PET Versus MRI Guided Re-irradiation in Patients With Recurrent Glioblastoma Multiforme(GLIAA) | unknown | Phase 2 | 200 | University Hospital FreiburgOTHER | 1 | Dec 16, 2010 | clinicaltrials |
| NCT01235845 | Dendritic Cell (DC) Activated Cytokine-induced Killer Cell (DCIK) Combined With DC Treatment for Glioma | unknown | Phase 1 / Phase 2 | 30 | Qingdao UniversityOTHER | 1 | Dec 3, 2010 | clinicaltrials |
| NCT01242566 | Temozolomide in Elderly Patients With KPS < 70(TAG) | completed | Phase 2 | 70 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 17, 2010 | clinicaltrials |
| NCT00562419 | CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan | unknown | Phase 2 | 72 | Adnexus, A Bristol-Myers Squibb R&D CompanyINDUSTRY | 1 | Oct 27, 2010 | clinicaltrials |
| NCT00535379 | SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme(SURGE01-07) | unknown | Phase 2 | 70 | Medical University InnsbruckOTHER | 2 | Aug 30, 2010 | clinicaltrials |
| NCT00643825 | Prolonged Adjuvant Temozolomide vs "Stop & Go" in Glioblastoma Patients(PATSGO) | unknown | Phase 2 | 64 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Jul 23, 2010 | clinicaltrials |
| NCT00936052 | Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma(HBO) | unknown | Phase 2 | 20 | Neurological Surgery, P.C.OTHER | 1 | Jul 16, 2010 | clinicaltrials |
| NCT00800917 | A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme | completed | Phase 2 | 12 | Rigshospitalet, DenmarkOTHER | 1 | Jun 2, 2010 | clinicaltrials |
| NCT00165477 | Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 10, 2010 | clinicaltrials |
| NCT01083719 | A Comparison of FDG-PET Versus MRI Based Target Volume Delineation in Glioblastoma and the Role of FDG-PET/CT in the Alteration of MRI Based Target Volumes. | unknown | Phase 2 | 15 | Medanta Institute of Clinical ResearchOTHER | 0 | Mar 10, 2010 | clinicaltrials |
| NCT00283556 | High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma | completed | Phase 1 / Phase 2 | 30 | Kentuckiana Cancer InstituteOTHER | 1 | Jan 20, 2010 | clinicaltrials |
| NCT00660283 | A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed By Dose Dense Therapy With Temozolomide For Newly Diagnosed Malignant High Grade Glioma(KARE003) | unknown | Phase 2 | 20 | Kentuckiana Cancer InstituteOTHER | 1 | Jan 20, 2010 | clinicaltrials |
| NCT00660621 | A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma(KARE004) | unknown | Phase 2 | 40 | Kentuckiana Cancer InstituteOTHER | 1 | Jan 20, 2010 | clinicaltrials |
| NCT00243490 | Photodynamic Therapy in the Treatment of Malignant Intracranial Tumors | withdrawn | Phase 2 | 5 | National Taiwan University HospitalOTHER | 1 | Jan 12, 2010 | clinicaltrials |
| NCT00730262 | Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme | terminated | Phase 2 | 40 | Thallion PharmaceuticalsINDUSTRY | 2 | Dec 30, 2009 | clinicaltrials |
| NCT00165360 | Prolonged Daily Temozolomide for Low-Grade Glioma | completed | Phase 2 | 46 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 2, 2009 | clinicaltrials |
| NCT00376103 | Radiation Boost for Newly Diagnosed Glioblastoma Multiforme | terminated | Phase 1 / Phase 2 | 3 | Methodist Healthcare - MemphisOTHER | 1 | Sep 18, 2009 | clinicaltrials |
| NCT00548938 | Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM | terminated | Phase 2 | 40 | Methodist Healthcare - MemphisOTHER | 1 | Sep 18, 2009 | clinicaltrials |
| NCT00944801 | Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 63 | University of RegensburgOTHER | 1 | Jul 23, 2009 | clinicaltrials |
| NCT00683761 | A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma | unknown | Phase 1 / Phase 2 | 64 | TransMolecularINDUSTRY | 1 | Jul 17, 2009 | clinicaltrials |
| NCT00032903 | This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma. | completed | Phase 1 / Phase 2 | 59 | Sigma-Tau Research, Inc.INDUSTRY | 1 | Jun 3, 2009 | clinicaltrials |
| NCT00114309 | 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma | unknown | Phase 2 | 66 | TransMolecularINDUSTRY | 1 | Apr 3, 2009 | clinicaltrials |
| NCT00040573 | Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma. | completed | Phase 1 / Phase 2 | 18 | TransMolecularINDUSTRY | 1 | Mar 31, 2009 | clinicaltrials |
| NCT00115440 | BNCT to Treat Glioma That Has Progressed Following Radiotherapy | completed | Phase 1 / Phase 2 | 22 | Boneca CorporationINDUSTRY | 1 | Jan 28, 2009 | clinicaltrials |
| NCT00365222 | Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma | terminated | Phase 2 | 1 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 22, 2009 | clinicaltrials |
| NCT00463073 | Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas | completed | Phase 2 | 32 | Rigshospitalet, DenmarkOTHER | 1 | Dec 11, 2008 | clinicaltrials |
| NCT00306618 | Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma | completed | Phase 2 | 27 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | Dec 10, 2008 | clinicaltrials |
| NCT00481455 | Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM) | completed | Phase 2 | 15 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | Nov 25, 2008 | clinicaltrials |
| NCT00115453 | Boron Neutron Capture Therapy (BNCT) as Treatment of Glioblastoma | terminated | Phase 1 / Phase 2 | 50 | Boneca CorporationINDUSTRY | 1 | Aug 18, 2008 | clinicaltrials |
| NCT00283543 | Radiation With Concomitant and Then Sequential Temozolomide in Malignant Glioma | unknown | Phase 2 | 40 | Kentuckiana Cancer InstituteOTHER | 1 | Oct 31, 2007 | clinicaltrials |
| NCT00250887 | Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research | completed | Phase 2 | 22 | University of ZurichOTHER | 1 | Oct 23, 2007 | clinicaltrials |
| NCT00521482 | Temozolomide vs. Temozolomide and Thalidomide Treatment in Recurrent Glioblastoma | unknown | Phase 2 | 40 | University of ZurichOTHER | 1 | Aug 28, 2007 | clinicaltrials |
| NCT00394628 | AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme | unknown | Phase 1 / Phase 2 | 60 | NovaceaINDUSTRY | 1 | May 30, 2007 | clinicaltrials |
| NCT00190723 | A Study of LY317615 in Patients With Brain Tumors | completed | Phase 2 | 120 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 26, 2007 | clinicaltrials |
| NCT00311857 | Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT) | unknown | Phase 1 / Phase 2 | 46 | Heidelberg UniversityOTHER | 1 | Sep 8, 2006 | clinicaltrials |
| NCT00029783 | Efficacy of Distant Healing in Glioblastoma Treatment | completed | Phase 2 | 150 | National Center for Complementary and Integrative Health (NCCIH)NIH | 1 | Aug 18, 2006 | clinicaltrials |
| NCT00028158 | Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain Cancer | completed | Phase 1 / Phase 2 | 65 | MediGeneINDUSTRY | 0 | Jun 24, 2005 | clinicaltrials |
Data updated 22 days agoSource updated May 16, 2011source: clinicaltrials